1. Home
  2. CPF vs DSGN Comparison

CPF vs DSGN Comparison

Compare CPF & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Central Pacific Financial Corp New

CPF

Central Pacific Financial Corp New

N/A

Current Price

$38.76

Market Cap

966.4M

Sector

Finance

ML Signal

N/A

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

N/A

Current Price

$10.38

Market Cap

853.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CPF
DSGN
Founded
1954
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
966.4M
853.8M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
CPF
DSGN
Price
$38.76
$10.38
Analyst Decision
Buy
Strong Buy
Analyst Count
5
8
Target Price
★ $42.75
$21.71
AVG Volume (30 Days)
123.2K
★ 441.1K
Earning Date
10-28-2026
11-17-2026
Dividend Yield
★ 3.08%
N/A
EPS Growth
★ 45.18
N/A
EPS
★ 2.46
N/A
Revenue
★ $51,817,000.00
N/A
Revenue This Year
$4.20
N/A
Revenue Next Year
$4.26
N/A
P/E Ratio
$15.78
★ N/A
Revenue Growth
★ 33.81
N/A
52 Week Low
$28.44
$6.23
52 Week High
$40.99
$17.25

Technical Indicators

Market Signals
Indicator
CPF
DSGN
Relative Strength Index (RSI) 64.87 41.94
Support Level $36.91 $9.83
Resistance Level $39.59 $11.29
Average True Range (ATR) 0.76 0.57
MACD 0.26 0.09
Stochastic Oscillator 91.84 39.53

Price Performance

Historical Comparison
CPF
DSGN

About CPF Central Pacific Financial Corp New

Central Pacific Financial Corp operates in the financial services sector in the United States. It is a full-service commercial bank offering a broad range of banking products and services, including accepting time and demand deposits and originating loans. Bank's deposits are insured by the Federal Deposit Insurance Corporation (FDIC) up to applicable limits. The bank is not a member of the Federal Reserve System. The company's loans include commercial loans, construction loans, commercial and residential mortgage loans, and consumer loans. The company derives income from interest and fees on loans, interest on investment securities, and fees received in connection with deposits and other services. It operates in single segment which is Banking operations.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: